This ASX fund manager is predicting big things for biotech shares

This ASX fund manager is bullish on biotech shares…
The post This ASX fund manager is predicting big things for biotech shares appeared first on The Motley Fool Australia. –

Platinum Asset Management Ltd (ASX: PTM) has long been one of the most followed funds management businesses on the ASX. Platinum was founded by the legendary ASX investor Kerr Neilson in the 1990s.

Ever since, the company has been a beacon of value investing on the ASX, even after Neilson’s departure in 2018. Now, Platinum is headed by its co-founder and Neilson protege Andrew Clifford.

Clifford recently sat down with Livewire for an interview. It makes for some interesting reading.

Discussing both Platinum’s history, and its prediction for the winning investing themes of the future, Clifford shared three insights.

Firstly, he sees a very bright and potentially lucrative shift towards the widespread adoption of electric vehicles. Platinum identifies the Korean company LG Chem as a major play in this space. Mr Clifford calls the company “one of the world’s leading suppliers of batteries”.

Secondly, Clifford identifies an opportunity in the search for replacements for single-use plastics. Pointing to Finnish forestry company UPM Kymmene Oy, he says he is excited about this company’s plans to turn timber products into bio-plastics.

Biotech shares for the future

But, thirdly, Clifford is looking to the biotech space for potential future gains. He predicts biotech will “kickstart a revolution in healthcare. Not only in the way we define and treat diseases but also in the way we manufacture products”:

The speed at which we’re coming up with potential solutions in the biotech world — whether it’s gene editing or mRNA — there are vast amounts of development in different areas of the sector that I think will transform the healthcare landscape…

The great lesson of the last year was obviously the way that mRNA technology could be used to create vaccines. We had investments in both BioNTech SE (NASDAQ: BNTX) and Moderna Inc (NASDAQ: MRNA) well ahead of COVID-19 and certainly stepped those up because we knew there would be an opportunity.

Clifford told Livewire that Dr Bianca Ogden, Platinum’s International Health Care fund manager, frequently points out how “molecular biology and computer science are converging” with Artificial Intelligence (AI).

In the report, Clifford said Odgen “believes that in the next 10 years we will start defining neurological disorders by their molecular profile akin to what we do in oncology”.

Exciting stuff.

The Motley Fool recently looked at some of the ASX’s best-performing biotech shares over the 2021 financial year so make sure to check those out next.

The post This ASX fund manager is predicting big things for biotech shares appeared first on The Motley Fool Australia.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of May 24th 2021

More reading

These ASX 200 shares are the most tightly held by individual insiders

Why Alkane, Carsales, Platinum, & Stockland shares are tumbling lower

Leading brokers name 3 ASX shares to sell today

ASX 200 midday update: Nearmap rockets, Incitec Pivot jumps

Why the Platinum (ASX:PTM) share price is sinking 7.5% on Tuesday

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Moderna Inc. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!